TrialThe lancet. HIV2026

Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis.

What the trial testedrandomised · 7,769 people · 2026

Randomised comparison

−68%−70% to −66%

Bigger than 9 in 10 on the map

As reported

RR 0.32, 95% CI 0.30–0.34

the abstract, start to end

… 0.57 in the placebo group (relative risk 0.32, 95% CI 0.30-0.34).

← favours treatmentfavours comparator →

could be chance

Lipids

RR 0.320.30–0.34

StatinsLipids

Statins × lipidshelps?mixed

unlikelylikely

0.500.50 without it

← favours treatmentfavours comparator →

this papermore certainless certain

1 / 5